High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB, Chen Y, Xie Z, Jiang J, Zhong YM, Guo WB, Yan WQ, Lv ZY, Lu DX, Liang HL, Xu FP, Yang JJ, Yang XN, Zhou Q, Zhang DK, Zhang Z, Chuai SK, Zhang HH, Wu YL, Zhang XC.
Feng HB, et al. Among authors: guo wb.
Thorac Cancer. 2021 Oct;12(19):2564-2573. doi: 10.1111/1759-7714.14137. Epub 2021 Sep 6.
Thorac Cancer. 2021.
PMID: 34490728
Free PMC article.